Analyst Price Target is $4.00
▲ +517.28% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Aethlon Medical in the last 3 months. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 517.28% upside from the last price of $0.65.
Current Consensus is
The current consensus among 0 polled investment analysts is to n/a stock in Aethlon Medical. This rating has held steady since July 2022, when it changed from a Buy consensus rating.
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.